Research Topic

Innovative Approaches for the Development of Novel PARP Inhibitors as Promising Targeted Cancer Therapies

About this Research Topic

Deficiency in DNA damage repair results in an increased risk of oncogenic transformation and genome instability. In the meantime, such a deficiency could be exploited for the treatment of different tumors through inducing excessive genome instability and catastrophic DNA damage. A higher demand of DNA repair components is required for the continuous DNA replication in cancer cells. On the account of incomplete DNA repair repertoire and oncogenic loss of some DNA repair effectors (e.g. BRCA), diverse cancer cells are addicted to some DNA repair pathways, such as Poly (ADP-ribose) polymerase (PARP)-related single-strand break repair pathway. Recently, there have been many indications that a broader population of cancer patients could benefit from PARP inhibition-based therapy far beyond those with germline BRCA1/2 mutated tumors.

PARPs are a family of enzymes that catalyze the transfer of ADP-ribose from nicotinamide adenine dinucleotide (NAD+) onto acceptor proteins. PARP-1, among this family, is the most widely investigated member due to its critical role as a DNA repair enzyme in the base excision repair pathway, and its association with a variety of cellular functions such as regulation of cell death, transcriptional modulation of gene expression, and inflammation. Subsequently, therapeutic strategies based on the inhibition of PARP-1, in the current medical era, emerged as promising drug targets for targeted cancer therapy with many clinical benefits in human malignancies treatment. Significant advances have been achieved in PARP-1 inhibitors, specifically, the FDA-approval of four PARPIs; Olaparib, Rucaparib, Niraparib and Talazoparib.

This Research Topic deals with manuscripts concerning with discovery and development of promising and effective PARPIs as new cancer therapies, through updating and modifying drug leads from the point of view of medicinal chemistry and drug design.

• Computer-Aided Drug Design of Novel PARP Inhibitors
• Synthesis and Biological Evaluation of Novel Small Molecules As PARP Inhibitors
• Natural and Semisynthetic Products as Potential PARP Inhibitors
• Drug Repositioning


Keywords: PARP inhibitors, drug design, organic synthesis, anticancer gents, drug repositioning


Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.

Deficiency in DNA damage repair results in an increased risk of oncogenic transformation and genome instability. In the meantime, such a deficiency could be exploited for the treatment of different tumors through inducing excessive genome instability and catastrophic DNA damage. A higher demand of DNA repair components is required for the continuous DNA replication in cancer cells. On the account of incomplete DNA repair repertoire and oncogenic loss of some DNA repair effectors (e.g. BRCA), diverse cancer cells are addicted to some DNA repair pathways, such as Poly (ADP-ribose) polymerase (PARP)-related single-strand break repair pathway. Recently, there have been many indications that a broader population of cancer patients could benefit from PARP inhibition-based therapy far beyond those with germline BRCA1/2 mutated tumors.

PARPs are a family of enzymes that catalyze the transfer of ADP-ribose from nicotinamide adenine dinucleotide (NAD+) onto acceptor proteins. PARP-1, among this family, is the most widely investigated member due to its critical role as a DNA repair enzyme in the base excision repair pathway, and its association with a variety of cellular functions such as regulation of cell death, transcriptional modulation of gene expression, and inflammation. Subsequently, therapeutic strategies based on the inhibition of PARP-1, in the current medical era, emerged as promising drug targets for targeted cancer therapy with many clinical benefits in human malignancies treatment. Significant advances have been achieved in PARP-1 inhibitors, specifically, the FDA-approval of four PARPIs; Olaparib, Rucaparib, Niraparib and Talazoparib.

This Research Topic deals with manuscripts concerning with discovery and development of promising and effective PARPIs as new cancer therapies, through updating and modifying drug leads from the point of view of medicinal chemistry and drug design.

• Computer-Aided Drug Design of Novel PARP Inhibitors
• Synthesis and Biological Evaluation of Novel Small Molecules As PARP Inhibitors
• Natural and Semisynthetic Products as Potential PARP Inhibitors
• Drug Repositioning


Keywords: PARP inhibitors, drug design, organic synthesis, anticancer gents, drug repositioning


Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.

About Frontiers Research Topics

With their unique mixes of varied contributions from Original Research to Review Articles, Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author.

Topic Editors

Loading..

Submission Deadlines

14 August 2020 Manuscript

Participating Journals

Manuscripts can be submitted to this Research Topic via the following journals:

Loading..

Topic Editors

Loading..

Submission Deadlines

14 August 2020 Manuscript

Participating Journals

Manuscripts can be submitted to this Research Topic via the following journals:

Loading..
Loading..

total views article views article downloads topic views

}
 
Top countries
Top referring sites
Loading..